Every SEC Form 3/4/5 on record for this filer (CIK 1690298) — 4 issuers, 52 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics, Inc. | Director | 2020-11-04 → 2026-06-09 | 9 | −$94,254 |
| PHAT | Phathom Pharmaceuticals, Inc. | President and Chief Executive · Director | 2019-10-24 → 2025-03-03 | 20 | −$996,633 |
| MYOV | Myovant Sciences Ltd. | Director · lapsed | 2016-11-17 → 2023-03-10 | 12 | −$1M |
| CELG | CELGENE CORP /DE/ | PRES., GLBL INFLAM. AND IMMUN. · lapsed | 2017-06-23 → 2019-11-22 | 18 | −$1M |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| PHAT | 2025-01-21 | Sell | 19,109 | $6.59 | $125,928 | 360,465 |
| ARQT | 2024-11-11 | Sell | 8,687 | $10.85 | $94,254 | 10,139 |
| PHAT | 2024-07-15 | Sell | 33,848 | $11.72 | $396,699 | 377,734 |
| PHAT | 2024-03-22 | Sell | 16,851 | $9.11 | $153,513 | 410,784 |
2 of 4 issuers are covered and open a security page; the rest are on file here only.